Vistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets
Portfolio Pulse from Vandana Singh
Vistagen Therapeutics Inc (NASDAQ:VTGN) announced positive results from its Phase 3 PALISADE-2 trial of fasedienol (PH94B) nasal spray for social anxiety disorder (SAD). The trial met its primary and secondary endpoints, demonstrating a statistically significant difference in average SUDS score during a public speaking challenge compared to placebo. The company's stock price surged by 1142.3% in premarket trading following the announcement.
August 07, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vistagen's stock price surged following the positive results from its Phase 3 trial of fasedienol nasal spray for SAD.
The positive results from the Phase 3 trial of Vistagen's fasedienol nasal spray for SAD, which is the first positive U.S. Phase 3 study of an investigational therapy for SAD in over 15 years, is a significant milestone for the company. This has led to a surge in the company's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100